Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astria Therapeutics Inc

5.09
+0.13002.62%
Volume:50.85K
Turnover:258.55K
Market Cap:287.25M
PE:-3.03
High:5.16
Open:5.06
Low:5.06
Close:4.96
Loading ...

Astria Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
1 hour ago

Top Premarket Decliners

MT Newswires Live
·
21 Apr

Astria Therapeutics Q4 EPS $(0.44) Beats $(0.45) Estimate

Benzinga
·
11 Mar

Press Release: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Dow Jones
·
11 Mar

TD Cowen Sticks to Its Buy Rating for Astria Therapeutics (ATXS)

TIPRANKS
·
10 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Mar

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
05 Mar

Astria Therapeutics Price Target Maintained With a $26.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

TD Cowen Remains a Buy on Astria Therapeutics (ATXS)

TIPRANKS
·
02 Mar

Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Analysts Are Bullish on Top Healthcare Stocks: Vericel (VCEL), Astria Therapeutics (ATXS)

TIPRANKS
·
28 Feb

Astria Therapeutics Initiates Alpha-Orbit Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

THOMSON REUTERS
·
27 Feb

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Business Wire
·
27 Feb

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Astria Therapeutics' Shares Rise After JMP Securities Initiates Coverage With Outperform Rating

MT Newswires Live
·
01 Feb

Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Jan

Astria Therapeutics Starts Phase 1a Trial of Atopic Dermatitis Treatment

MT Newswires Live
·
23 Jan

Astria initiates Phase 1a Trial of STAR-0310 trial, sees proof of concept in Q3

TIPRANKS
·
23 Jan

Astria Therapeutics Inc - Early Proof-of-Concept Results Expected in Q3 2025

THOMSON REUTERS
·
23 Jan